Theranexus SA (FR:ALTHX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Theranexus partners with Synerlab to produce and commercialize its innovative pediatric miglustat oral solution for Niemann-Pick type C disease, targeting a 2026 market entry. This collaboration aims to address the unmet needs of pediatric patients and exploit a potential €200 million market in Europe. With lower financial requirements than other projects, Theranexus anticipates significant returns and market exclusivity.
For further insights into FR:ALTHX stock, check out TipRanks’ Stock Analysis page.